We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

102 hedge funds and large institutions have $729M invested in Dianthus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

369% more call options, than puts

Call options by funds: $2.68M | Put options by funds: $572K

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

6% more capital invested

Capital invested by funds: $685M → $729M (+$43.1M)

4.22% more ownership

Funds ownership: 117.38% → 121.6% (+4.2%)

4% more funds holding

Funds holding: 98 → 102 (+4)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

28% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 40

Holders
102
Holders Change
+4
Holders Change %
+4.08%
% of All Funds
1.34%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
18
Increased
29
Reduced
40
Closed
14
Calls
$2.68M
Puts
$572K
Net Calls
+$2.11M
Net Calls Change
+$3.03M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$28.1M
2
BBA
Baker Bros. Advisors
New York
+$14.8M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.33M
4
Goldman Sachs
Goldman Sachs
New York
+$5.46M
5
Millennium Management
Millennium Management
New York
+$3.66M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$14M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$13.7M
3
B
Braidwell
Connecticut
-$6.81M
4
GPP
Great Point Partners
Connecticut
-$4.99M
5
BlackRock
BlackRock
New York
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$84.7M +$1.16M +61,579 +1%
VPC
2
Vestal Point Capital
New York
$59.6M +$28.1M +1,499,931 +88%
RCM
3
RA Capital Management
Massachusetts
$53.4M – – –
FFM
4
Fairmount Funds Management
Pennsylvania
$50.4M +$122K +6,500 +0.2%
BCLSI
5
Bain Capital Life Sciences Investors
Massachusetts
$46.2M -$3.89M -207,457 -8%
OCA
6
Octagon Capital Advisors
New York
$43.6M – – –
DTC
7
Deep Track Capital
Connecticut
$41.6M -$2.34M -124,554 -5%
APM
8
Avidity Partners Management
Texas
$32.5M +$413K +22,000 +1%
TCM
9
TCG Crossover Management
California
$28M – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$26.9M +$6.33M +337,206 +30%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$25.9M -$1.77M -94,427 -6%
BlackRock
12
BlackRock
New York
$25.3M -$4.82M -257,020 -16%
AllianceBernstein
13
AllianceBernstein
Tennessee
$21.9M +$2.8M +149,200 +15%
VA
14
VR Adviser
New York
$18.6M -$14M -744,373 -43%
5VM
15
5AM Venture Management
California
$18.3M -$806K -42,986 -4%
State Street
16
State Street
Massachusetts
$15.3M +$1.13M +60,458 +8%
BBA
17
Baker Bros. Advisors
New York
$14.7M +$14.8M +789,759 New
CCM
18
Catalio Capital Management
New York
$13.9M -$318K -16,944 -2%
Citadel Advisors
19
Citadel Advisors
Florida
$12.4M +$3.64M +194,164 +41%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$9.04M -$603K -32,118 -6%
WP
21
Woodline Partners
California
$7.46M +$1.88M +100,000 +33%
Goldman Sachs
22
Goldman Sachs
New York
$6.79M +$5.46M +291,162 +397%
TCM
23
Tang Capital Management
California
$4.93M – – –
CS
24
Candriam SCA
Luxembourg
$4.48M -$151K -8,034 -3%
SCM
25
Sio Capital Management
New York
$4.4M +$2.23M +119,073 +102%
1
2 3 4 5

DNTH Hedge Fund Activity: Q2 2025 in Review

102 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2025, worth a combined $729M — up 6.3% from $685M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DNTH positions and 14 closed out — a net gain of 4 holders — while 29 added to existing stakes and 40 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $28.1M. The largest seller was VR Adviser, cutting an estimated $14M.

  • 102 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2025, up from 98 in Q1 2025.
  • Funds reported $729M of Dianthus Therapeutics stock for Q2 2025, up 6.3% quarter-over-quarter.
  • 18 funds opened new Dianthus Therapeutics positions in Q2 2025 and 14 closed out, a net change of +4 holders.
  • The largest Dianthus Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $28.1M added.
  • The largest Dianthus Therapeutics seller in Q2 2025 was VR Adviser, an estimated $14M sold.

Based on aggregated 13F filings for Q2 2025.